Subconjunctival Versus Direct Mitomycin C in Trabeculectomy

• Status: Completed
• Trial end date: 2019-04-14
• Target enrollment: 0
• Participant gender: All

Summary

Trabeculectomy is routinely used as a surgical treatment for open angle glaucoma. Success of trabeculectomy is greatly augmented by the use of antimetabolites to inhibit wound healing, specifically Mitomycin C (MMC). MMC can be applied to the eye at various sites, concentrations and times. This study aims to compare the two application routes that are commonly employed: subconjunctival pre-operative injection and intraoperative direct scleral application in terms of IOP lowering effect, bleb appearance and complications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Mitomycin; Mitomycins

Criteria

Inclusion Criteria:

• medically uncontrolled glaucoma

• healthy and freely mobile conjunctiva in superior bulbar region

Exclusion Criteria:

• previous incisional glaucoma surgery

• no light perception vision

• pregnant or nursing women

• iris neovascularization or proliferative retinopathy

• iridocorneal endothelial syndrome

• chronic or recurrent uveitis

• steroid-induced glaucoma

• pathologic myopia or refractive error less than -6.00 diopters

• unwillingness or inability to give consent

• inability to return for scheduled protocol visits